Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA9 | Q16790 | 11/20 | 0.55 |
| ▸ | CA12 | O43570 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917735 | 0.92 | CA2 (0.54) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL5675377 | 0.84 | PDGFRB (0.58) | CA1CA2CA9CA12MAPT | |
| SCHEMBL3754376 | 0.83 | LIPG (0.47) | CA1CA2CA9CA12 | |
| SCHEMBL30015709 | 0.83 | LIPG (0.47) | CA1CA2CA9CA12 | |
| SCHEMBL12491377 | 0.82 | CA2 (0.52) | CA1CA2CA9CA12MAPT | |
| SCHEMBL12491113 | 0.82 | MEN1 (0.60) | CA1CA2CA9CA12MAPT | |
| SCHEMBL423849 | 0.82 | PDGFRB (0.54) | MAPTMEN1ALDH1A1KMT2APDGFRB | |
| SCHEMBL556699 | 0.82 | PDGFRB (0.46) | CA1CA2CA9CA12MAPT | |
| SCHEMBL15932600 | 0.81 | RAB9A (0.55) | CA1CA2CA9MAPTMEN1 | |
| SCHEMBL29895479 | 0.79 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221374-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CA1 4553/4885CA2 3721/4885CA9 3235/4885 |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CA1 4680/4885CA2 3855/4885CA9 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.